NEW YORK (GenomeWeb) – GIMDx announced today that it has signed an exclusive distribution agreement for IncellDx's single-cell immune-oncology and oncology diagnostic products in China.

Under the terms of the agreement, GIMDx will supply its China-based parent company Guangzhou Improve Medical Instruments with IncellDx component products, which will be kitted and co-labeled for the Chinese in vitro diagnostic market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.